- Johnson & Johnson (NYSE:JNJ) unit announces that the FDA has approved ACUVUE Abiliti Overnight Therapeutic Lenses.
- This is the first and only FDA approved orthokeratology (ortho-k) contact lens for the management of myopia.
- Abiliti Overnight contact lenses are expected to be available in the U.S. by the end of 2021.
- Abiliti Overnight contact lenses are optimized by the use of corneal topography, refractive error and other measurements connected to an innovative fitting software, which provides a precise measure of the corneal shape, and accurately guides the eye care professional through the fitting process for consistent and successful first fit rates of ~90%§.
- The FDA approval of Abiliti Overnight stems from the collaboration of Johnson & Johnson Vision with Menicon to bring forward therapeutic contact lenses for the treatment of myopia under the ACUVUE Abiliti Brand.